Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia-Reference-Cited by-同舟云学术

Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia

Published:2018-10-17 Issue:1 Volume:96 Page:57-66
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Marcelletti John F.¹,Sikic Branimir I.²³,Cripe Larry D.⁴,Paietta Elisabeth⁵

Affiliation:

1. Department of Clinical Development; Kanisa Pharmaceuticals; San Diego California

2. Department of Medicine; Stanford University; Stanford California

3. Oncology Division; Stanford University; Stanford, California

4. Department of Hematology/Oncology; Indiana University Simon Cancer Center; Indianapolis Indiana

5. Oncology Department; Albert Einstein College of Medicine; Bronx New York

Funder

National Institutes of Health

National Cancer Institute of the National Institutes of Health

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cyto.b.21737/fullpdf

Reference35 articles.

1. Molecular pathways: Regulation and therapeutic implications of multidrug resistance;Chen;Clin Cancer Res,2012

2. Drug resistance: Still a daunting challenge to the successful treatment of AML;Shaffer;Drug Resist Updat,2012

3. Mechanisms of tumor cell resistance to the current targeted-therapy agents;Khamisipour;Tumour Biol,2016

4. Disrupting P-glycoprotein function in clinical settings: What can we learn from the fundamental aspects of this transporter;Chung;Am J Cancer Res,2016

5. Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia;Bartholomae;Pediatr Blood Cancer,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype;Cancer Chemotherapy and Pharmacology;2023-08-21

2. Effectors of the Type VI Secretion System Have the Potential to Be Modified into Antimicrobial Peptides;Microbiology Spectrum;2023-08-17

3. Fluorochromes for the Study of the Cell Features;Flow Cytometry Today;2022

4. Multiplex Single‐Cell Analysis of Cancer Cells Enables Unbiased Uncovering Subsets Associated with Cancer Relapse: Heterogeneity of Multidrug Resistance in Precursor B‐ALL;ChemMedChem;2021-11-29

5. Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome;Drug Resistance Updates;2020-12